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Abstract: Altered expression of COX-2 and overproduction of prostaglandins, particularly prostaglandin E2, are common 
in malignant tumors. Consequently, non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) attenuate tumor net growth, tumor 
related cachexia, improve appetite and prolong survival. We have also reported that COX-inhibition (indomethacin) inter-
fered with early onset of tumor endothelial cell growth, tumor cell proliferation and apoptosis. It is however still unclear 
whether such effects are restricted to metabolic alterations closely related to eicosanoid pathways and corresponding regu-
lators, or whether a whole variety of gene products are involved both up- and downstream effects of eicosanoids. Therefore, 
present experiments were performed by the use of an in vivo, intravital chamber technique, where micro-tumor growth and 
related angiogenesis were analyzed by microarray to evaluate for changes in global RNA expression caused by indometha-
cin treatment. 
Indomethacin up-regulated 351 and down-regulated 1852 genes signiﬁ  cantly (p < 0.01); 1066 of these genes had unknown 
biological function. Genes with altered expression occurred on all chromosomes. 
Our results demonstrate that indomethacin altered expression of a large number of genes distributed among a variety of 
processes in the carcinogenic progression involving angiogenesis, apoptosis, cell-cycling, cell adhesion, inﬂ  ammation as 
well as fatty acid metabolism and proteolysis. It remains a challenge to distinguish primary key alterations from secondary 
adaptive changes in transcription of genes altered by cyclooxygenase inhibition.
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Introduction
It is well established that non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) attenuate tumor net growth 
(Peterson, 1986), where provision of unselective prostaglandin synthase inhibitors, particularly indo-
methacin, attenuates systemic inﬂ  ammation due to reduced prostaglandin production. This leads to 
decreased host appearance of acute phase proteins in both tumor-bearing mice and cancer patients 
(Cahlin et al. 2000b; Peluffo et al. 2004; McMillan et al. 1995). Such effects are related to reduced 
tumor growth, improved appetite and attenuation of cachexia with subsequent prolongation of survival 
in experimental models (Gelin et al. 1991; Cahlin et al. 2000a; Lönnroth et al. 1995). Similar improve-
ments have also been repeatedly observed in unselected cancer patients on systemic anti-inﬂ  ammatory 
treatment (Lundholm et al. 1994; Lundholm et al. 2004). In a recent study we reported that unspeciﬁ  c 
COX-inhibition (indomethacin) interfered with early onset of tumor endothelial cell growth, tumor cell 
proliferation and apoptosis (Lönnroth et al. 1995), observations that are similar to our ﬁ  ndings in pros-
taglandin receptor subtype knock out mice (Axelsson et al. 2005). It is however still unclear whether 
such effects are mainly restricted to metabolic alterations closely related to eicosanoid and prostanoid 
pathways or whether a whole variety of gene products are involved up- and downstream of effects by 
eicosanoids. Therefore, microarray technique was used to evaluate overall changes in global RNA 
expression in early onset of micro-tumor growth and related angiogenesis.126
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Material and Methods
Tumor models and animal groups
Tumor model
A methylcholanthrene induced sarcoma (MCG 
101) was used in present experiments. This 
tumor model has been continuously transplanted 
in vivo at our laboratory for more than 25 years. 
The tumor was originally induced chemically 
as a sarcoma, while recent histological evalua-
tion revealed that few tumor cells, if any, have 
characteristics of a sarcoma. Therefore, our 
tumor should rather be classified as a low or 
undifferentiated rapidly growing epithelial-like 
solid tumor. It has a reproducible and exponen-
tial growth pattern with a doubling time of 
55–60 hours in vivo. It leads to 100% tumor 
take and does not give rise to visible metastases 
within the time period it kills the host. The 
tumors comprise 15–20 % of the body weight 
of the tumor bearing animals at the time of 
spontaneous death due to anorexia and cachexia. 
MCG 101 cells produce increased systemic 
levels of prostaglandin E2, and COX-1/COX-2 
inhibition by indomethacin, with normalized 
systemic levels of PGE2, reduced tumor growth, 
improved nutritional state and prolonged host 
survival (Gelin et al. 1991; Cahlin et al. 2000a). 
These effects by indomethacin were in part due 
to decreased tumor cell proliferation and 
increased apoptosis as well as attenuated angio-
genesis (Axelsson et al. 2005).
MCG-101 tumor cells for intravital chamber 
inoculation were maintained in Mc Coy’s 5 A 
medium (MP Biomedicals, Inc., Aurora, Ohio, 
USA) supplemented with fetal calf serum (FCS, 
10%), penicillin (100 U/ml), streptomycin (100 
μg/ml) and L-glutamine (292 μg/ml). Cells were 
split 1/5 once weekly with a medium change in 
between (Mc Coy´s 5A + 2% FCS, penicillin, 
streptomycin and L-glutamin as mentioned above). 
The viability of the tumor cells was >99 % evalu-
ated by trypan blue exclusion and microscopic 
examination before experiment. At start of exper-
iments, cells were trypsinized and suspended in 
Mc Coy´s 5A medium at a concentration of 1.15 
× 10
5 cells/μl, 0,5 μl was inoculated into the intra-
vital chamber as described. Animals were sacri-
ﬁ  ced at day 5 and micro tumors were immediately 
frozen in liquid nitrogen and kept at –80 °C until 
RNA extraction. 
Animal groups
Adult, weight stable, female, wild type C57 black 
mice (n = 24) were used. The animals were housed 
in a temperature controlled room (24 °C) with a 
12 hour light / dark schedule. The mice were 
housed in separate cages during the experiments 
to avoid interference with the subcutaneously 
placed intravital chamber. All animals were 
allowed initial adaptation for 3 days following 
operation to attain stable body weight and normal 
food intake before experiments started with free 
access to ordinary rodent chow (ALAB AB, Stock-
holm, Sweden) and water ad libitum under all 
experimental conditions.
All mice were randomly assigned to treatment 
(n = 12) and control groups (n = 12) before implan-
tation with tumor cell suspensions. Treatment 
groups received indomethacin (Confortid, 5 mg/
ml, Dumex-Alpharma) provided in the drinking 
water for 5 days corresponding to 6 μg / ml 
drinking water (Gelin et al. 1991; Cahlin et al. 
2000a; Lönnroth et al. 1995; Lönnroth et al. 2001). 
The appropriate dilution of indomethacin in the 
drinking water was calculated based on daily 
normal water consumptions of 3–4 ml water/
mouse/day. This corresponds to indomethacin of 
1 μg/g bw/day. Controls received ordinary drinking 
water. Indomethacin provision started two days 
before tumor cell inoculation. 
Intravital chamber and surgical 
techniques
The dorsal skin fold chamber in the mouse was 
prepared as described earlier (Axelsson et al. 
1997). Mice were anaesthetized with i.p. injection 
of 0.15 ml from a 1 ml stock-solution composed 
of 0.4 ml  Ketalar
® (50 mg/ml; Parke-Davis), 0.05 
ml  Rompun
® vet (20 mg/ml; Bayer), and 0.55 ml 
physiological saline. The dorsal skin was shaved. 
The mice were kept at constant temperature of 36-
37 °C by means of a heating pad during the proce-
dure. A 20 mm long midline incision was made in 
the dorsal skin. Blunt dissection was used to free 
the skin from underlying tissue before introducing 
the chamber into the skin fold. The chamber was 
ﬁ  xed to the skin by 4–0 sutures and the midline 
incision used for the installation of the chamber 127
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was closed with two 4–0 stitches. The skin covering 
one side of the central hole of the chamber was 
removed to expose the micro vascular tree of the 
contralateral subcutaneous tissue. Tumor cells 
(5.75 × 10
4) were inoculated onto the upper tissue 
layer of the chamber preparation by means of a 
Hamilton needle (10 μl). Small volumes of tumor 
cells were applied in order to avoid disseminated 
growth of tumor in the chamber. The access 
chamber was closed by cover glass after 
inoculation.
Microscopy
Observations on tumor growth were made by 
microscopy in a Nikon Eclipse E400 microscope 
with Nikon Plan 4X/0,10 objective and Nikon 
Digital Camera DXM 1200. Photographical docu-
mentations were performed immediately after 
implantation of tumor cells at day 0 and at day 5 
following tumor cell implantation. Digital pictures 
were kept in a computer for subsequent analysis. 
Typical tumor graphs have been published else-
where (Axelsson et al. 2005; Axelsson et al. 
1997).
Image analysis of vascular beds
Image analyses were based on analysis of a given 
area by use of a digital photo across the tumor area. 
The area was composed of the tumor and its near 
surroundings and was the identical area in photos 
from day 0 and day 5. The centrum of a photo 
corresponded to the central part of the tumor based 
on visual analysis. For image analyses we used the 
computer program Easy Image Analysis 2000, 
Tekno Optik AB, and applied a technique to quan-
tify the area (mm
2) of tumor related blood vessels 
and the size of the tumor area in the same plane 
(mm
2). Tumor related vascular area is the differ-
ence in vascular area between day 5 and day 0. 
This represents the appearance of net vessel forma-
tion around the tumor during ﬁ  ve days, which was 
reported to be significantly reduced by 
indomethacin(Axelsson et al. 2005). Five days 
tumor growth was necessary to identify microtu-
mors and corresponding vascular net works for 
isolation of RNA. 
RNA extraction and ampliﬁ  cation
Tumors from experiment 1 with 6 indomethacin-
treated mice and 5 untreated control mice were 
pooled within groups, 3 + 3 (Indo 1A, 1B) and 
3 + 2 (Ctrl 1C, 1D). Tumors from experiment 2 
with 6 indomethacin-treated and 6 control mice 
were pooled within groups in the same way, (Indo 
2A, 2B and Ctrl 2C, 2D). Total RNA Isolation 
Microdissected Cryosections Kit (QIAGEN 
Sciences, Maryland, U.S.A.) was used. Tissue 
disruption was done by aspiration with a syringe 
through 18 gauge needle 5x in lysis buffer. Quality 
and quantity of RNA were checked in an Agilent 
2100 BioAnalyzer with RNA 6000 Nano Assay kit 
(Agilent Technologies, Palo Alto, CA, U.S.A.). 
Concentrations of RNA were measured in a Nano-
Drop (ND-1000A) spectrophotometer (NanoDrop 
Technologies, Inc.). Isolated tumor weight ranged 
from 8.4 to 16 mg (Indo) and 7.2 to 20.1 mg (Ctrl) 
wet weight and total RNA amount ranged from 4.1 
to 10.1 μg (booth groups). RNA was linearly ampli-
ﬁ  ed with BD Smart mRNA Ampliﬁ  cation Kit (BD 
Biosciences Clontech, Palo Alto, CA, USA). 
Unampliﬁ  ed total RNA used in the ampliﬁ  cation 
reaction ranged from 425 ng to 946 ng with an 
efﬁ  ciency of 160 to 240 x ampliﬁ  cation based on 
the assumption that 5% of the total RNA fraction 
consists of polyA + mRNA. Ampliﬁ  ed mRNA was 
checked for quality and quantity as mentioned 
above for total RNA.
cDNA Microarray proﬁ  ling and data 
analysis
Expression array, Whole Mouse Genome Oligo 
Microarray (Agilent Technologies), containing 
44290 features, including positive and negative 
control spots, was used. Four-hundred nanograms 
of ampliﬁ  ed mRNA fractions from indomethacin-
treated animals in experiment 1 (pool of  200 ng 
1A and 200 ng 1B = test) were labeled with 
Cyanine 3-dCTP (Amersham Biosciences) in 
cDNA synthesis reaction with Agilent Fluorescent 
Direct Label Kit. Fourhundred nanograms of 
ampliﬁ  ed mRNA fractions from untreated control 
mice in experiment 1 (pool of 200 ng 1C and 200 
ng 1D = ctrl) were labeled with Cyanine 5-dCTP 
in parallel with the test-fraction. Hybridizations 
were performed during 18 hours with test- versus 
control cDNA followed by post-hybridization 
washes according to “in situ Hybridization Kit 
Plus” (Agilent Technologies) instructions. Micro-
arrays were dried with nitrogen gas in a laminar 
ﬂ  ow bench and images were quantiﬁ  ed on Agilent 
G2565 AA microarray scanner and ﬂ  uorescence 128
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intensities were extracted using the Feature Extrac-
tion software program (Agilent technologies). 
Dye-normalized, outlier- and background-
subtracted values were further analyzed in Gene-
Spring software program, imported with the FE 
Plug-in (Agilent Technologies). Ampliﬁ  ed mRNAs 
from experiment 2 were analyzed in the same way 
as in experiment 1 as a replicate. Technical repli-
cates of experiment 1 and 2 were performed in a 
second run and the computer-based analyses were 
performed on all four series. 
Gene expression in healthy, inbred mice was 
tested in muscle tissue from two individuals for 
assessment of the overall microarray variability. 
PolyA + selected RNA was extracted and 400 ng 
from mouse 1 were labeled with Cyanine 3-dCTP 
and 400 ng from mouse 2 were labeled with 
Cyanine 5-dCTP followed by hybridization to the 
same array targets with a ratio of 1.31 ± 0.03 
(M ± SD) which conﬁ  rms the validity of presented 
ﬁ  ndings. 
Statistics
Comparisons between several groups were 
performed by factorial analysis of variance 
(ANOVA). The ratio between expressed transcripts 
in tumor tissue of MCG 101 inoculates from study 
versus control animals were calculated in the 
GeneSpring software program. Genes with 
p-values outside the 99% confidence limit 
(p < 0.01) of the overall analytical variability as 
derived by t-testing were regarded to reflect 
significantly up- or down-regulated genes as 
deﬁ  ned by the software producer.
Results
24 mice were used in these experiments divided 
on 12 study animals and 12 controls. One mouse 
in the control group died initially due to the 
experimental procedures subsequently to implan-
tation of the vascular chamber and was excluded 
from further analyses.
Indomethacin treatment reduced tumor area 
(p < 0.03), while the reduced tumor related vascular 
area did not reach statistical signiﬁ  cance as observed 
and reported elsewhere in a larger group of animals 
(Axelsson et al. 2005) (Fig. 1). Tumor vascular area 
is positively correlated to the tumor area (not shown) 
as reported (Axelsson et al. 2005). 
41 534 transcripts (genes) were analyzed 
(Fig. 2). Indomethacin treatment up-regulated 351 
and down-regulated 1852 genes (p < 0,01). 1066 
of these 2203 genes had unknown gene products 
and unknown biological function(s) of the corre-
sponding protein. Such genes were therefore 
excluded for further consideration (Fig. 2). Genes 
signiﬁ  cantly affected by indomethacin were located 
on all chromosomes as shown in (Fig. 3) with 
distribution according to functional aspects as 
shown in Table 1. The ten most up- and down-
regulated genes according to the amounts of tran-
script following indomethacin treatment are shown 
in Table 2. Genes altered by indomethacin and 
strictly related to arachidonic acid metabolism are 
shown in Figure 4. Signiﬁ  cantly altered genes for 
regulation of important but different aspects of the 
carcinogenic process (inﬂ  ammation, angiogenesis, 
apoptosis, cell cycle, proliferation, cell adhesion, 
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carbohydrate and fatty acid metabolism, proteol-
ysis) are shown in the Appendix ordered by their 
magnitude in transcription comparing indometh-
acin treated tumors versus controls. 
Discussion
It is well-recognized that non-steroidal anti-inﬂ  am-
matory drugs (NSAIDs), particularly indometh-
acin, attenuate tumor net growth (Peterson 1986), 
reduced tumor related cachexia, improved appetite 
and prolonged survival in tumor bearing mice 
(Gelin et al. 1991; Cahlin et al. 2000a; Lönnroth 
et al. 1995), and in part also in cancer patients 
(Lundholm et al. 1994; Lundholm et al. 2004). 
There is also evidence from population based, case 
control and clinical trials that regular use of 
NSAIDs may reduce the relative risk to develop 
colorectal adenomas (Baron et al. 2003; Sandler 
et al. 2003) and colorectal cancer (Smalley and 
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Figure 2. Stepwise analysis of global gene expression assessed by microarray technique. Genes in red boxes are subjected to functional 
considerations in Figure 4 and Table 4–6. 
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Figure 3. Distribution of tumor tissue genome wide expression of RNA transcripts (genes) signiﬁ  cantly up- and down-regulated during in-
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unknown localization). 130
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DuBois 1997; Thun et al. 1991; Williams et al. 
1999; Giovannucci et al. 1994; Giovannucci et al. 
1995; Smalley et al. 1999). Altered expression of 
COX-2 and overproduction of prostaglandins are 
common in colorectal cancers (Eberhart et al. 1994; 
Marnett and DuBois 2002; Williams et al. 1999; 
Joo et al. 2002), breast (Rolland et al. 1980), gastric 
(Uefuji et al. 2001), esophagus (Shamma et al. 
2000), pancreatic (Juuti et al. 2006), bile duct 
(Hayashi et al. 2001), papillary thyroid (Siironen 
et al. 2006), malignant pheochromocytomas 
(Salmenkivi et al. 2001), urinary tract (Tuna et al. 
2004), prostate (Tkacz et al. 2005), cervical 
(Kulkarni et al. 2001), retinoblastoma (Karim et al. 
2000) and lung cancer (Wolff et al. 1998). Elevated 
levels of COX-2 and PGE2 are also seen in prema-
lignant conditions such as Barrett´s esophagus 
(Kandil et al. 2001) and colorectal adenomas (Khan 
et al. 2001). Thus, there are strong evidence that 
both COX-1 and COX-2 are of importance in 
several cancer forms in man. (Gupta et al. 2003; 
Huang et al. 2006). 
We have earlier reported that indomethacin 
increased tumor cell apoptosis and reduced tumor 
cell proliferation and endothelial cell growth in 
animal studies (Axelsson et al. 2005), where 
unselective prostaglandin synthase inhibitors, 
(indomethacin), attenuate systemic inﬂ  ammation 
reﬂ  ected by reduction in plasma concentrations of 
prostaglandin E2 and acute phase proteins (Cahlin 
et al. 2000b; Peluffo et al. 2004; McMillan et al. 
1995). It is assumed that tumor reducing effects by 
indomethacin are caused by blocking prostaglandin 
production (Vane 1971), with competitive inhibi-
tion of substrate binding at COX- isoenzymes. 
Highly selective COX-2 inhibitors have retained 
anti-tumor effects, despite a lack of COX-1 
inhibition, suggesting that COX-2 mediators are 
as well important for tumor development (Sheng 
et al. 1997; Evans 2003; Peluffo et al. 2004; 
Huang et al. 2006). The present study was based 
on intravital chamber (Axelsson et al. 1997) and 
microarray technique in order to evaluate overall 
changes in global RNA synthesis caused by 
indomethacin treatment on initial tumor growth 
to further map out important genetic areas 
behind tumor reducing effects by cyclooxy-
genase inhibition. 
Indomethacin reduced tumor size as in earlier 
studies (Axelsson et al. 2005) and altered expres-
Table 1. The number of up- and down-regulated genes, regarded either stimulatory or inhibitory in function for 
progression of microtumors and related angiogenesis. 
   Up-regulated  Down-regulated  P-value  (sign  test)
Angiogenesis 1  4  n.s.
 Stimulatory  genes  1  3  n.s.
 Inhibitory  genes  0  1  n.s.
Apoptosis 9  22  0.05
 Stimulatory  genes  9  19  n.s.
 Inhibitory  genes  0  3  n.s.
Carbohydrate metabolism 4  5  n.s.
 Stimulatory  genes  4  5  n.s.
 Inhibitory  genes  0  0  n.s.
Cell cycle & cell proliferation 8  39  <0.01
 Stimulatory  genes  7  31  <0.01
 Inhibitory  genes  1  6  n.s.
Cell adhesion 3  19  <0.01
 Stimulatory  genes  3  19  <0.01
 Inhibitory  genes  0  0  n.s.
Fatty acid metabolism 3  16  <0.01
 Stimulatory  genes  3  16  0.01
 Inhibitory  genes  0  0  n.s.
Inﬂ  ammation 9  14  n.s.
 Stimulatory  genes  8  13  n.s.
 Inhibitory  genes  1  1  n.s.
Proteolysis 5  26  <0.01
 Stimulatory  genes  5  26  <0.01
 Inhibitory  genes  0  0  n.s131
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sion of 2 203 genes out of 41 534 (5,3%). These 
genes were widely and relatively uniformly spread 
over the entire genome on all chromosomes. Indo-
methacin down-regulated ﬁ  ve times as many genes 
being up-regulated. Affected genes were predom-
inantly stimulatory in function. Thus, effects by 
indomethacin were overall down-regulating 
stimulatory genes. However, indomethacin inﬂ  u-
enced on the expression of a large number of genes 
responsible for important steps in the carcinogenic 
process. Genes with mainly reduced expression 
involved apoptosis, cell cycle and proliferation, 
cell adhesion, fatty acid metabolism and proteol-
ysis, while effects on angiogenesis, carbohydrate 
metabolism and inﬂ  ammation displayed both up- 
and down-regulation. 
We have previously reported that tumor effects 
by indomethacin involve apoptosis and cell prolif-
eration in vivo (Axelsson et al. 2005), as conﬁ  rmed 
by others in vitro (Huang et al. 2006). Earlier and 
resent studies indicate that COX-2 derived PGE2 
are involved in the control of programmed cell 
death (Sheng et al. 1998; Huang et al. 2006), 
although exact mechanisms are unknown. PGE2 
may reduce apoptotic rates by increasing levels of 
antiapoptotic proteins like Bcl-2 (Sheng et al. 
1998), Mcl-1 or other key mediators as NF-κB 
(Poligone and Baldwin 2001) and by activation of 
two main apoptotic pathways: the death receptor 
and mitochondrial pathways (Huang et al. 2006). 
Such results agree with our present in vivo ﬁ  ndings, 
which indicate that indomethacin down-regulated 
Mcl-1, while Bcl-2 and TNF-receptor associated 
factor 5 were significantly increased. Genes 
involved in the NF-κB cascade were both up- and 
down-regulated by indomethacin. Prior studies 
have shown that PGE2 stimulates cell proliferation 
in colorectal cancer (Sheng et al. 2001), although 
downstream pathways are still unknown. There are 
indications that cell proliferation is stimulated by 
activation of the epidermal growth factor receptor 
(EGFR) (Yoshimoto et al. 2002). Tumor growth is 
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also stimulated by the oncogene Ras, which 
induces cell proliferation, cell transformation and 
cell survival by activation of Raf-MEK-ERK and 
PI3K-Akt pathways. Indomethacin treatment in 
present experiments down-regulated Raf and Akt 
genes, which would reduce tumor cell prolifera-
tion. Genes responsible for the production of EGF 
and EGF-receptor were not signiﬁ  cantly changed, 
while other genes involving cell proliferation 
mainly showed reduced expression as reported 
elsewhere (Lönnroth et al. 2001).
Angiogenesis is though to play a central role in 
cancer progression (Folkman 1971). Main proan-
giogenic factors are vascular endothelial growth 
factor (VEGF) and ﬁ  broblast growth factor 1 & 2 
(acidFGF & basicFGF). There is also evidence that 
COX-2 plays a role in tumor-associated angiogen-
esis (Williams et al. 2000; Oshima et al. 1996) by 
modulation of proangiogenic factors with correla-
tions between COX-2 and VEGF expression in 
tumor tissue (Joo et al. 2003). PGE2 is then thought 
to be the mediator behind COX-2 activities in tumor 
angiogenesis (Hernandez et al. 2001). Both selective 
and nonselective COX-inhibitors can however 
reduce tumor angiogenesis, by inhibiting production 
of proangiogenic factors and subsequent prolifera-
tion, migration and tube formation of endothelial 
cells (Axelsson et al. 2005; Peterson 1986; Tsujii 
et al. 1998; Masferrer et al. 2000; Skopinska-
Rozewska et al. 1998; Sawaoka et al. 1999). In the 
present analysis the gene coding for one of three 
forms of VEGF (VEGF-A) was down-regulated by 
indomethacin whereas the other two (VEGF-B & 
C) were unaffected. AcidFGF showed a trend 
towards down-regulation, while basicFGF displayed 
a trend to up-regulation. Other genes in angiogenesis 
were mainly down-regulated. Our results therefore 
support that indomethacin affects tumor angiogen-
esis in addition to other processes more related to 
tumor cell proliferation (Axelsson et al. 2005). 
Malignant disease is also characterized by 
attenuation of cell mediated anti-tumor immune 
response. Probably directed in part by PGE2, 
based on reduced production of anti-tumor Th1 
cytokines (TNFα, IFNγ and IL-2) (Harris et al. 
2002) and increased production of Th2 cyto-
kines (IL-4, IL-10 and IL-6) (Shreedhar et al. 
1998; Huang et al. 1998; Della Bella et al. 
1997). In present experiments the gene coding 
for TNFα was up-regulated, while genes coding 
for mentioned cytokines were not changed by 
indomethacin. Our previous results imply that 
main tumor reducing effects by indomethacin are 
caused by blockade of prostaglandin production 
(Vane 1971). Accordingly, genes coding for these 
enzymes in prostaglandin biosynthesis were 
decreased by indomethacin including the COX-2 
enzyme. This suggests that indomethacin also acts 
on transcription of cyclooxygenases.
Genes in control of fatty acid and protein 
metabolism were signiﬁ  cantly and highly down-
regulated by indomethacin, while genes for carbo-
hydrate metabolism seemed to be both up- and 
down-regulated. These observations may 
contribute to reported beneficial overall host-
metabolic effects by indomethacin attenuating 
catabolism caused by a growing tumor (Gelin 
et al. 1991; Lundholm et al. 2004). Distant 
metastases are the major cause of death in 
cancer. Over-expression of COX-2 and increased 
production of PGE2 may promote metastatic 
potential and tumor cell invasiveness (Tsujii 
et al. 1997), while treatment with NSAIDs 
reduced this imbalance (Lundholm et al. 1994; 
Yamauchi et al. 2003; Yao et al. 2003). The 
PI3K-Akt pathway is highly important in regu-
lating tumor cell migration and invasion where 
PGE2 is known to stimulate this pathway (Sheng 
et al. 2001). In present experiments the gene 
coding for Akt was significantly down-regulated 
and genes coding for proteins regulating cell 
adhesion were likewise mainly down-regulated 
by indomethacin. 
In conclusion, this study has evaluated the 
magnitude of net overall changes on whole genome 
transcription in micro-tumors during a period of 
unspecific cyclooxygenase blockade by indo-
methacin. The results, derived in vivo by applica-
tion of microarray, demonstrate an overwhelming 
number of inﬂ  uences by indomethacin of which 
inhibitory effects (down-regulation) appeared to 
dominate. It remains a challenge to distinguish 
primary key effects from secondary adaptive 
alterations in transcription of all these affected 
genes by NSAID treatment. 
Acknowledgements
Supported in parts by grants from the Swedish 
Cancer Society (2014), the Swedish Research 
Council (08712), Tore Nilson Foundation, Assar 
Gabrielsson Foundation (AB Volvo), Jubileum-
skliniken foundation, IngaBritt & Arne Lundberg 
Research Foundation, Swedish and Göteborg 134
Axelsson et al
Cancer Informatics 2007:3 
Medical Societies and the Medical Faculty, Göte-
borg University, VGR 19/00, 1019/00
References
Axelsson, H., Bagge, U. and Lundholm, K. et al. 1997. A one-piece plexi-
glass access chamber for subcutaneous implantation in the dorsal 
skin fold of the mouse. Int. J. Microcirc. Clin.Exp., 17:328–9.
Axelsson, H., Lönnroth, C. and Wang, W. et al. 2005. Cyclooxygenase in-
hibition in early onset of tumor growth and related angiogenesis 
evaluated in EP1 and EP3 knockout tumor-bearing mice. Angiogen-
esis, 8:339–48.
Baron, J.A., Cole, B.F. and Sandler, R.S. et al. 2003. A randomized trial of 
aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348:891–9.
Cahlin, C., Gelin, J. and Delbro, D. et al. 2000a. Effect of cyclooxygenase 
and nitric oxide synthase inhibitors on tumor growth in mouse tumor 
models with and without cancer cachexia related to prostanoids. 
Cancer Res., 60:1742–9.
Cahlin, C., Korner, A. and Axelsson, H. et al. 2000b. Experimental cancer 
cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, 
interferon-gamma, and tumor necrosis factor alpha evaluated in gene 
knockout, tumor-bearing mice on C57 Bl background and eicosanoid-
dependent cachexia. Cancer Res., 60:5488–93.
Della Bella, S., Molteni, M. and Compasso, S. et al. 1997. Differential ef-
fects of cyclo-oxygenase pathway metabolites on cytokine production 
by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids, 
56:177–84.
Eberhart, C.E., Coffey, R.J. and Radhika, A. et al. 1994. Up-regulation of 
cyclooxygenase 2 gene expression in human colorectal adenomas 
and adenocarcinomas. Gastroenterology, 107:1183–8.
Evans, J.F. 2003. Rofecoxib (Vioxx), a speciﬁ  c cyclooxygenase-2 inhibitor, 
is chemopreventive in a mouse model of colon cancer. Am. J. Clin. 
Oncol., 26:S62–5.
Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. 
J. Med., 285:1182–6.
Gelin, J., Andersson, C. and Lundholm, K. 1991. Effects of indomethacin, 
cytokines, and cyclosporin A on tumor growth and the subsequent 
development of cancer cachexia. Cancer Res., 51:880–5.
Giovannucci, E., Egan, K.M. and Hunter, D.J. et al. 1995. Aspirin and the 
risk of colorectal cancer in women. N. Engl. J. Med., 333:609–14.
Giovannucci, E., Rimm, E.B. and Stampfer, M.J. et al. 1994. Aspirin use 
and the risk for colorectal cancer and adenoma in male health profes-
sionals. Ann. Intern. Med., 121:241–6.
Gupta, R.A., Tejada, L.V. and Tong, B.J. et al. 2003. Cyclooxygenase-1 is 
overexpressed and promotes angiogenic growth factor production in 
ovarian cancer. Cancer Res., 63:906–11.
Harris, S.G., Padilla, J. and Koumas, L. et al. 2002. Prostaglandins as 
modulators of immunity. Trends Immunol., 23:144–50.
Hayashi, N., Yamamoto, H. and Hiraoka, N. et al. 2001. Differential expres-
sion of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells 
and bile duct neoplasm. Hepatology, 34:638–50.
Hernandez, G.L., Volpert, O.V. and Iniguez, M.A. et al. 2001. Selective 
inhibition of vascular endothelial growth factor-mediated angiogen-
esis by cyclosporin A: roles of the nuclear factor of activated T cells 
and cyclooxygenase 2. J. Exp. Med., 193:607–20.
Huang, M., Stolina, M. and Sharma, S. et al. 1998. Non-small cell lung cancer 
cyclooxygenase-2-dependent regulation of cytokine balance in lympho-
cytes and macrophages: up-regulation of interleukin 10 and down-regu-
lation of interleukin 12 production. Cancer Res., 58: 1208–16.
Huang, R.H., Chai, J. and Tarnawski, A.S. 2006. Identiﬁ  cation of speciﬁ  c 
genes and pathways involved in NSAIDs-induced apoptosis of human 
colon cancer cells. World J. Gastroenterol., 12:6446–52.
Joo, Y.E., Kim, H.S. and Min, S.W. et al. 2002. Expression of cyclooxy-
genase-2 protein in colorectal carcinomas. Int. J. Gastrointest. 
Cancer, 31:147–54.
Joo, Y.E., Rew, J.S. and Seo, Y.H. et al. 2003. Cyclooxygenase-2 overexpression 
correlates with vascular endothelial growth factor expression and tumor 
angiogenesis in gastric cancer. J. Clin. Gastroenterol., 37: 28–33.
Juuti, A., Louhimo, J. and Nordling, S. et al. 2006. Cyclooxygenase-2 ex-
pression correlates with poor prognosis in pancreatic cancer. J. Clin. 
Pathol., 59:382–6.
Kandil, H.M., Tanner, G. and Smalley, W. et al. 2001. Cyclooxygenase-2 
expression in Barrett’s esophagus. Dig. Dis. Sci., 46:785–9.
Karim, M.M., Hayashi, Y. and Inoue, M. et al. 2000. Cox-2 expression in 
retinoblastoma. Am. J. Ophthalmol., 129:398–401.
Khan, K.N., Masferrer, J.L. and Woerner, B.M. et al. 2001. Enhanced cy-
clooxygenase-2 expression in sporadic and familial adenomatous 
polyposis of the human colon. Scand J. Gastroenterol., 36:865–9.
Kulkarni, S., Rader, J.S. and Zhang, F. et al. 2001. Cyclooxygenase-2 is overex-
pressed in human cervical cancer. Clin. Cancer Res., 7:429–34.
Lundholm, K., Daneryd, P. and Korner, U. et al. 2004. Evidence that long-
term COX-treatment improves energy homeostasis and body com-
position in cancer patients with progressive cachexia. Int. J. Oncol., 
24:505–12.
Lundholm, K., Gelin, J. and Hyltander, A. et al. 1994. Anti-inﬂ  ammatory 
treatment may prolong survival in undernourished patients with 
metastatic solid tumors. Cancer Res., 54:5602–6.
Lönnroth, C., Andersson, M. and Lundholm, K. 2001. Indomethacin and 
telomerase activity in tumor growth retardation. Int. J. Oncology, 
18:929–937.
Lönnroth, C., Svaninger, G. and Gelin, J. et al. 1995. Effects related to in-
domethacin prolonged survival and decreased tumor growth in a 
mouse tumor model with cytokine dependent cancer cachexia. Int. 
J. Oncol., 7:1405–1413.
Marnett, L.J. and DuBois, R.N. 2002. COX-2: a target for colon cancer 
prevention. Annu. Rev. Pharmacol. Toxicol., 42:55–80.
Masferrer, J.L., Leahy, K.M. and Koki, A.T. et al. 2000. Antiangiogenic and 
antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 
60:1306–11.
McMillan, D.C., Leen, E. and Smith, J. et al. 1995. Effect of extended 
ibuprofen administration on the acute phase protein response in 
colorectal cancer patients. Eur. J. Surg. Oncol., 21:531–4.
Oshima, M., Dinchuk, J.E. and Kargman, S.L. et al. 1996. Suppression of 
intestinal polyposis in Apc delta716 knockout mice by inhibition of 
cyclooxygenase 2 (COX-2). Cell, 87:803–9.
Peluffo, G.D., Stillitani, I. and Rodriguez, V.A. et al. 2004. Reduction of 
tumor progression and paraneoplastic syndrome development in 
murine lung adenocarcinoma by nonsteroidal antiinﬂ  ammatory drugs. 
Int. J. Cancer, 110:825–30.
Peterson, H.I. 1986. Tumor angiogenesis inhibition by prostaglandin syn-
thetase inhibitors. Anticancer Res., 6:251–3.
Poligone, B. and Baldwin, A.S. 2001. Positive and negative regulation of 
NF-kappaB by COX-2: roles of different prostaglandins. J. Biol. 
Chem., 276:38658–64.
Rolland, P.H., Martin, P.M. and Jacquemier, J. et al. 1980. Prostaglandin in 
human breast cancer: Evidence suggesting that an elevated prosta-
glandin production is a marker of high metastatic potential for neo-
plastic cells. J. Natl. Cancer Inst., 64:1061–70.
Salmenkivi, K., Haglund, C. and Ristimaki, A. et al. 2001. Increased expres-
sion of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. 
Endocrinol. Metab., 86:5615–9.
Sandler, R.S., Halabi, S. and Baron, J.A. et al. 2003. A randomized trial of 
aspirin to prevent colorectal adenomas in patients with previous 
colorectal cancer. N. Engl. J. Med., 348:883–90.
Sawaoka, H., Tsuji, S. and Tsujii, M. et al. 1999. Cyclooxygenase inhibitors 
suppress angiogenesis and reduce tumor growth in vivo. Lab Invest., 
79:1469–77.
Shamma, A., Yamamoto, H. and Doki, Y. et al. 2000. Up-regulation of 
cyclooxygenase-2 in squamous carcinogenesis of the esophagus. 
Clin. Cancer Res., 6:1229–38.135
RNA expression in cancer cells in early growth and angiogenesis
Cancer Informatics 2007:3 
Sheng, H., Shao, J. and Kirkland, S.C. et al. 1997. Inhibition of human 
colon cancer cell growth by selective inhibition of cyclooxygenase-2. 
J. Clin. Invest., 99:2254–9.
Sheng, H., Shao, J. and Morrow, J.D. et al. 1998. Modulation of apoptosis 
and Bcl-2 expression by prostaglandin E2 in human colon cancer 
cells. Cancer Res., 58:362–6.
Sheng, H., Shao, J. and Washington, M.K. et al. 2001. Prostaglandin E2 
increases growth and motility of colorectal carcinoma cells. J. Biol. 
Chem., 276:18075–81.
Shreedhar, V., Giese, T. and Sung, V.W. et al. 1998. A cytokine cascade 
including prostaglandin E2, IL-4, and IL-10 is responsible for UV-
induced systemic immune suppression. J. Immunol., 160:3783–9.
Siironen, P., Ristimaki, A. and Narko, K. et al. 2006. VEGF-C and COX-2 
expression in papillary thyroid cancer. Endocr. Relat. Cancer, 
13:465–73.
Skopinska-Rozewska, E., Piazza, G.A. and Sommer, E. et al. 1998. Inhibi-
tion of angiogenesis by sulindac and its sulfone metabolite (FGN- 1): 
a potential mechanism for their antineoplastic properties. Int. J. Tis-
sue React., 20:85–9.
Smalley, W., Ray, W.A. and Daugherty, J. et al. 1999. Use of nonsteroidal 
anti-inﬂ  ammatory drugs and incidence of colorectal cancer: a popu-
lation-based study. Arch. Intern. Med., 159:161–6.
Smalley, W.E. and DuBois, R.N. 1997. Colorectal cancer and nonsteroidal 
anti-inﬂ  ammatory drugs. Adv. Pharmacol., 39:1–20.
Thun, M.J., Namboodiri, M.M. and Heath, C.W. Jr. 1991. Aspirin use and 
reduced risk of fatal colon cancer. N. Engl. J. Med., 325:1593–6.
Tkacz, V.L., Tohnya, T.M. and Figg, W.D. 2005. Cyclooxygenase-2 and 
angiogenesis in prostate cancer. Cancer Biol. Ther., 4:813–4.
Tsujii, M., Kawano, S. and DuBois, R.N. 1997. Cyclooxygenase-2 expres-
sion in human colon cancer cells increases metastatic potential. Proc. 
Natl. Acad. Sci. U.S.A., 94:3336–40.
Tsujii, M., Kawano, S. and Tsuji, S. et al. 1998. Cyclooxygenase regulates 
angiogenesis induced by colon cancer cells [published erratum ap-
pears in Cell 1998 Jul 24;94(2):following 271]. Cell, 93:705–16.
Tuna, B., Yorukoglu, K. and Gurel, D. et al. 2004. Signiﬁ  cance of COX-2 
expression in human renal cell carcinoma. Urology, 64:1116–20.
Uefuji, K., Ichikura, T. and Mochizuki, H. 2001. Expression of cyclooxy-
genase-2 in human gastric adenomas and adenocarcinomas. J. Surg. 
Oncol., 76:26–30.
Vane, J.R. 1971. Inhibition of prostaglandin synthesis as a mechanism of 
action for aspirin-like drugs. Nat. New Biol., 231:232–5.
Williams, C.S., Shattuck-Brandt, R.L. and DuBois., R.N. 1999. The role of 
COX-2 in intestinal cancer. Expert Opin. Investig. Drugs, 8:1–12.
Williams, C.S., Tsujii, M. and Reese, J. et al. 2000. Host cyclooxygenase-2 
modulates carcinoma growth. J. Clin. Invest., 105:1589–94.
Wolff, H., Saukkonen, K. and Anttila, S. et al. 1998. Expression of cyclo-
oxygenase-2 in human lung carcinoma. Cancer Res., 58:4997–5001.
Yamauchi, T., Watanabe, M. and Hasegawa, H. et al. 2003. The potential 
for a selective cyclooxygenase-2 inhibitor in the prevention of liver 
metastasis in human colorectal cancer. Anticancer Res., 23:245–9.
Yao, M., Kargman, S. and Lam, E.C. et al. 2003. Inhibition of cyclooxy-
genase-2 by rofecoxib attenuates the growth and metastatic potential 
of colorectal carcinoma in mice. Cancer Res., 63:586–92.
Yoshimoto, T., Takahashi, Y. and Kinoshita, T. et al. 2002. Growth stimula-
tion and epidermal growth factor receptor induction in cyclooxygen-
ase-overexpressing human colon carcinoma cells. Adv. Exp. Med. 
Biol., 507:403–7.136
Axelsson et al
Cancer Informatics 2007:3 
Appendix 
Signiﬁ  cantly up- and down-regulated tumor tissue genes controlling important steps of tumor progression during 
indomethacin treatment of MCG 101 inoculated mice.
ANGIOGENESIS_______________________________________________________________________________________________________________ 
Gene name  Accession 
number 
Ratio t-test 
p-value 
Product Biological  process 
Nte  NM_015801  1,19  0,0097  neuropathy target esterase  angiogenesis 
Hif1a  NM_010431  0,73  0,0047  hypoxia inducible factor 1, alpha subunit  angiogenesis; response to hypoxia 
AK004663  AK004663  0,71  0,0004  caveolin 2  negative regulation of endothelial cell proliferation 
Enpep NM_007934  0,70  0,0021  glutamyl  aminopeptidase  angiogenesis 
Robo4 NM_028783  0,68  0,0083  roundabout  homolog  4  angiogenesis 
APOPTOSIS___________________________________________________________________________________________________________________
Gene name  Accession 
number 
Ratio t-test 
p-value 
Product Biological  process 
Cidea  NM_007702  2,70  0,0080  cell death-inducing DNA fragmentation 
factor
apoptosis
Bcl2a1c  NM_007535  1,97  0,0074  B-cell phospholi/lymphoma 2 related protein 
A1c
apoptosis
Traf5  NM_011633  1,96  0,0009  Tnf receptor-associated factor 5  apoptosis; positive regulation of cell proliferation 
Mnt  NM_010813  1,82  0,0087  max binding protein  cell aging; regulation of apoptosis & cell cycle 
BC012955  BC012955  1,76  0,0097  tribbles homolog 3  apoptosis 
Ppp1r13b  NM_011625  1,73  0,0011  protein phosphatase 1, regulatory subunit 
13B
apoptosis
Ddit3  NM_007837  1,68  0,0080  DNA-damage inducible transcript 3  cell cycle arrest; apoptosis 
Clca2  NM_030601  1,24  0,0010  chloride channel calcium activated 2  apoptosis 
Gadd45g  NM_183358  1,16  0,0013  growth arrest and DNA-damage-inducible 
45 gamma 
apoptosis; cell cycle 
Mcl1  NM_008562  0,86  0,0013  myeloid cell leukemia sequence 1  apoptosis 
AK020218  AK020218  0,82  0,0096  Tial1 cytotoxic granule-associated RNA 
binding protein 
apoptosis
AK129340  AK129340  0,77  0,0073  programmed cell death 6 interacting protein  apoptosis 
AK079110  AK079110  0,74  0,0034  Bcl-2-associated transcription factor  positive regulation of apoptosis 
Hif1a  NM_010431  0,73  0,0047  hypoxia inducible factor 1, alpha subunit  apoptosis 
AK012111  AK012111  0,72  0,0003  cell division cycle and apoptosis regulator 1  apoptosis 
Casp2 NM_007610  0,71  0,0037  caspase  2  apoptosis 
Casp6 NM_009811  0,69  0,0038  caspase  6  apoptosis 
Cflar  NM_009805  0,68  0,0089  CASP8 & FADD-like apoptosis regulator 
isoform 1 & 2 
apoptosis
2810413N20Rik  NM_134141  0,67  0,0045  cytokine induced apoptosis inhibitor 1  anti-apoptosis 
AF121215  AF121215  0,67  0,0096  muc2  apoptosis; negative regulation of cell proliferation 
Unc5d NM_153135  0,66  0,0028  netrin  receptor  Unc5h4  apoptosis 
Pdcd8  NM_012019  0,62  0,0061  programmed cell death 8  DNA fragmentation & mitochondrial changes of 
apoptosis
Pten  NM_008960  0,61  0,0050  phosphatase and tensin homolog  apoptosis; negative regulation of cell cycle 
Casp12 NM_009808  0,57  0,0055  caspase  12  apoptosis 
Thoc1  NM_153552  0,57  0,0099  THO complex 1  apoptosis 
Cycs NM_007808  0,52  0,0092  cytochrome  c  apoptosis 
Lgals7  NM_008496  0,52  0,0054  galactose binding lectin  apoptosis 
Api5  NM_007466  0,51  0,0073  apoptosis inhibitor 5  anti-apoptosis 
Bad NM_007522  0,51  0,0090  Bcl-associated  death  promoter  apoptosis 
Ube1c  NM_011666  0,50  0,0061  ubiquitin-activating enzyme E1C  apoptosis; cell cycle 
Birc6  NM_007566  0,47  0,0082  baculoviral IAP repeat-containing 6  anti-apoptosis 
CARBONHYDRATE 
METABOLISM_________________________________________________________________________________________________
Gene name  Accession 
number 
Ratio t-test 
p-value 
Product Biological  process 
Chst4 NM_011998 2,21  0,0082  carbohydrate sulfotransferase 4  expression of 6-sulfo sialyl Lewis X ( L-selectin 
ligand displayed by CD34) 
Pmm1 NM_013872 1,98  0,0031  phosphomannomutase 1  mannose biosynthesis & metabolism 
Ppp1r1a NM_021391 1,87  0,0056  protein phosphatase 1, subunit 1A  glycogen metabolism 137
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Ins1 NM_008386 1,83  0,0072  insulin I  glucose metabolism & transport 
Man2b1  NM_010764  0,80  0,0088  mannosidase 2, alpha B1  carbohydrate metabolism 
Ppara  NM_011144  0,70  0,0082  peroxisome phospholipids activated 
receptor alpha 
glucose metabolism 
Large NM_010687  0,68  0,0069  like-glycosyltransferase  carbohydrate  biosynthesis 
BC005552  BC005552  0,67  0,0017  asparagine synthetase  asparagine biosynthesis; glutamine metabolism 
Bad  NM_007522  0,51  0,0090  Bcl-associated death promoter  glucose catabolism; glucose homeostasis 
Man2a1  NM_008549  0,45  0,0078  mannosidase 2, alpha 1  carbohydrate metabolism 
CELL CYCLE & CELL PROLIFERATION____________________________________________________________________________________________
Gene name  Accession 
number 
Ratio t-test 
p-value
Product Biological  process 
Cdc37  NM_016742  2,10  0,0048  cell division cycle 37 homolog  cell cycle 
Traf5  NM_011633  1,96  0,0009  Tnf receptor-associated factor 5  positive regulation of cell proliferation; apoptosis 
Mnt  NM_010813  1,82  0,0087  max binding protein  regulation of cell cycle; cell aging; regulation of 
apoptosis
Pard3  NM_033620  1,68  0,0038  partitioning-defective protein 3 homolog  cell cycle 
Chc1  NM_133878  1,62  0,0053  chromosome condensation 1  cell cycle; mitosis 
Myg1  NM_021713  1,55  0,0033  melanocyte proliferating gene 1  proliferation 
Mapk3  NM_011952  1,41  0,0098  mitogen activated protein kinase 3  cell cycle 
Gadd45g  NM_011817  1,16  0,0013  growth arrest & DNA-damage-inducible 45 
gamma
cell cycle 
Ccng1  NM_009831  0,84  0,0077  cyclin G1  cell cycle; mitosis 
Ccnt1  NM_009833  0,84  0,0045  cyclin T1  cell cycle 
AW209059  NM_023058  0,78  0,0048  tyrosine- & threonine specific cdc2-inhibitory 
kinase
cell cycle 
U27177  U27177  0,77  0,0089  retinoblastoma-like protein 1  negative regulation of cell cycle 
Orc3l  NM_015824  0,76  0,0090  origin recognition complex, subunit 3-like  DNA replication 
Cul4b  NM_028288  0,76  0,0041  cullin 4B  cell cycle 
X61753  X61753  0,75  0,0038  heat shock factor 1  negative regulation of cell proliferation 
Prim2  NM_008922  0,74  0,0075  DNA primase, p58 subunit  DNA replication 
AB003502  AB003502  0,74  0,0023  G1 to S phase transition 1  G1/S transition of mitotic cell cycle; cell 
proliferation; cell cycle 
Cspg6  NM_007790  0,72  0,0010  chondroitin sulfate proteoglycan 6  DNA repair; cell cycle; meiosis; mitosis 
Prim1  AK089063  0,71  0,0047  DNA primase small subunit  DNA replication 
Mina  NM_025910  0,71  0,0009  myc induced nuclear antigen  cell proliferation 
Pdgfb  NM_011057  0,71  0,0072  platelet derived growth factor, B polypeptide  cell proliferation; cell cycle 
Ppara NM_011144  0,70  0,0082  peroxisome    hospholipids  activated 
receptor alpha 
regulation of transcription 
Gsg2  NM_010353  0,67  0,0096  germ cell-specific gene 2  cell cycle 
Mcm8  NM_025676  0,67  0,0028  minichromosome maintenance deficient 8  DNA replication; cell cycle 
Chek1  NM_007691  0,66  0,0055  checkpoint kinase 1 homolog  G2/M transition of mitotic cell cycle 
Cdk2  NM_016756  0,66  0,0011  cyclin-dependent kinase 2 isoform 1&2  cell cycle 
03-sep  NM_011889  0,65  0,0017  septin 3  cell cycle 
Orc2l  NM_008765  0,63  0,0000  origin recognition complex, subunit 2  DNA replication 
AF129738  AF129738  0,63  0,0059  cullin 3  cell cycle 
AK052506  AK052506  0,63  0,0002  cyclin J  cell cycle 
AK044216  AK044216  0,62  0,0074  nucleolar protein 5  cell growth
Pten  NM_008960  0,61  0,0050  phosphatase and tensin homolog  negative regulation of cell cycle; induction of 
apoptosis
Tax1bp3  NM_029564  0,60  0,0031  Tax1 binding protein 3  negative regulation of cell proliferation 
Mcm7  NM_008568  0,58  0,0042  minichromosome maintenance protein 7  cell cycle; cell proliferation 
Mafk NM_010757  0,59  0,0068  v-maf  cell  cycle 
Igfbp7  NM_008048  0,56  0,0084  insulin-like growth factor binding protein 7  cell growth
BC031460  BC031460  0,54  0,0066  anaphase-promoting complex subunit 10  cell cycle; mitosis 
Cks2  NM_025415  0,53  0,0072  CDC28 protein kinase regulatory subunit 2  cell cycle 
Stag1  NM_009282  0,53  0,0028  stromal antigen 1  cell cycle; chromosome segregation; mitosis 
BC053028  BC053028  0,52  0,0004  large tumor suppressor 2  negative regulation of cell cycle 
Ube1c  NM_011666  0,50  0,0061  ubiquitin-activating enzyme E1C  cell cycle; apoptosis 
BC029198  BC029198  0,50  0,0015  M-phase phosphoprotein 10 
Ccnh  NM_023243  0,49  0,0009  cyclin H  cell cycle 
Ect2  NM_007900  0,45  0,0038  ect2 oncogene  cell cycle 
AY259532 AY259532  0,44  0,0051  M-phase  phosphoprotein 
Top1  NM_009408  0,44  0,0031  topoisomerase I  DNA replication 
CELL ADHESION_______________________________________________________________________________________________________________
Gene name  Accession 
number 
Ratio t-test 
p-value
Product Biological  process 138
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Pard3  NM_033620  1,68  0,0038  partitioning-defective protein 3 homolog  cell-cell adhesion; cytokinesis 
Selpl NM_009151  1,33  0,0044  selectin  cell  adhesion 
BC039767  BC039767  1,26  0,0080  protein tyrosine phosphatase, receptor type 
F
cell adhesion 
Hapln1  NM_013500  1,17  0,0046  hyaluronan and proteoglycan link protein 1  cell adhesion 
Rgmb  AK047390  0,79  0,0067  repulsive guidance molecule B  cell adhesion 
AK077250  AK077250  0,79  0,0043  plakophilin 4  cell adhesion 
AK039018  AK039018  0,78  0,0021  neuroligin 3  cell adhesion 
Ptpru  NM_011214  0,77  0,0066  protein tyrosine phosphatase, receptor type 
L
cell adhesion 
AK016518  AK016518  0,76  0,0095  Down syndrome cell adhesion molecule  cell adhesion 
Catnd2  NM_008729  0,74  0,0051  catenin delta 2  cell adhesion 
Col6a1  NM_009933  0,72  0,0018  procollagen, type VI, alpha 1  cell adhesion 
Itgb2l  NM_008405  0,70  0,0076  integrin beta 2-like  cell-matrix adhesion 
AF169388  AF169388  0,68  0,0094  procollagen, type IV, alpha 4  cell adhesion 
AK034300  AK034300  0,67  0,0058  brain link protein 2  cell adhesion 
Omd NM_012050  0,67  0,0017  osteomodulin  cell  adhesion 
Lims1  NM_026148  0,61  0,0076  LIM & senescent cell antigen-like domains 1  cell-matrix adhesion 
NM_017383  NM_017383  0,61  0,0094  contactin 6  cell adhesion 
Col5a1  NM_015734  0,59  0,0049  procollagen, type V, alpha 1  cell adhesion 
X15050  X15050  0,59  0,0040  neural cell adhesion molecule 1  cell adhesion 
AK032156  AK032156  0,58  0,0096  protocadherin beta 14  cell adhesion 
Fbln5  NM_011812  0,54  0,0082  fibulin 5  cell adhesion 
Pscdbp  NM_139200  0,52  0,0011  pleckstrin homology binding protein  cell adhesion 
Pcdhb22  NM_053147  0,47  0,0088  protocadherin beta 22  cell adhesion 
FATTY ACID
METABOLISM_______________________________________________________________________________________________________
Gene name  Accession 
number 
Ratio t-test 
p-value
Product Biological  process 
Cidea  NM_007702  2,70  0,0080  cell death-inducing DNA fragmentation 
factor
lipid metabolism
BC026669  BC026669  2,58  0,0037  acetyl-Coenzyme A acyltransferase 1  fatty acid metabolism 
Galgt1 NM_008080  1,29  0,0049  beta-1,4-N-acetylgalactosaminyltransferase  lipid  glycosylation 
AY259499  AY259499  0,74  0,0072  nephrocystin 3  lipid metabolism
Ppara  NM_011144  0,70  0,0082  peroxisome phospholipids activated 
receptor alpha 
fatty acid metabolism 
Crot  NM_023733  0,69  0,0093  carnitine O-octanoyltransferase  fatty acid metabolism & transport 
AK083617  AK083617  0,67  0,0049  RIKEN cDNA 4933425A18  fatty acid biosynthesis 
1600020H07Rik AK041686  0,63  0,0089  2-hydroxyphytanoyl-CoA lyase lipid  metabolism
Pla1a  NM_134102  0,62  0,0081  phospholipase A1 member A  lipid metabolism
Ch25h  NM_009890  0,61  0,0024  cholesterol 25-hydroxylase  cholesterol metabolism 
BC026817  BC026817  0,59  0,0058  acetoacetyl-CoA synthetase  fatty acid metabolism 
Sftpb  NM_147779  0,58  0,0054  surfactant associated protein B  lipid metabolism
Hsd17b7 NM_010476  0,57  0,0039  hydroxysteroid  dehydrogenase  7  steroid  biosynthesis 
Gnpat  NM_010322  0,53  0,0037  glyceronephosphate O-acyltransferase  ether lipid biosynthesis; phospholipids biosynthesis 
AF017175  AF017175  0,52  0,0056  carnitine palmitoyltransferase 1a  fatty acid metabolism & transport 
3632410F03Rik  NM_028721  0,51  0,0042  nephrocystin 3  lipid metabolism
Hadhb  AK033462  0,64  0,0070  hydroxyacyl-Coenzyme A dehydrogenase / 
3-ketoacyl-Coenzyme A thiolase / enoyl-
Coenzyme A hydratase 
fatty acid beta-oxidation 
Acox2  NM_053115  0,59  0,0086  acyl-Coenzyme A oxidase 2  fatty acid beta-oxidation 
Elovl6  NM_130450  0,54  0,0055  ELOVL family member 6  fatty acid elongation 
INFLAMMATION________________________________________________________________________________________________________________
Gene name  Accession 
number 
Ratio t-test 
p-value
Product Biological  process 
M13540  M13540  2,96  0,0054  histocompatibility 2, class II antigen A, beta 
1
antigen presentation & processing (exogenous 
peptide antigen via MHC class II) 
Rmcs1  NM_207105  2,34  0,0010  response to metastatic cancers 1  antigen presentation & processing (exogenous 
peptide antigen via MHC class II) 
AK008094  AK008094  1,96  0,0097  humoral immune response 
Gab3  NM_181584  1,84  0,0078  growth factor receptor bound protein 2  macrophage differentiation 
BC037477  BC037477  1,64  0,0017  adaptor-related protein complex 3  antigen presentation & processing (exogenous lipid 
antigen); positive regulation of NK T-cell 
differentiation139
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AJ298147  AJ298147  1,45  0,0006  defensin beta 7  defense response to bacteria 
H2-M10.2  NM_177923  1,44  0,0010  histocompatibility 2, M region locus 10.2  antigen presentation & processing (endogenous 
antigen via MHC class I) 
BC021779  BC021779  1,33  0,0030  Fms interacting protein  negative regulation of macrophage differentiation 
Ccl19  NM_011888  1,24  0,0051  chemokine ligand 19  chemotaxis; immune response; inflammatory 
response
Ly6d  NM_010742  1,19  0,0028  lymphocyte antigen 6 complex, locus D  defense response 
Gadd45g  NM_011817  1,16  0,0013  growth arrest & DNA-damage-inducible 45 
gamma
T-helper 1 cell differentiation; interferon-gamma 
biosynthesis 
AK080873  AK080873  0,91  0,0023  toll-like receptor adaptor molecule 2  regulation of I-kappaB kinase / NF-kappaB 
cascade; regulation of cytokine production 
BC030872 BC030872  0,83  0,0088  attractin-like  1  inflammatory  response 
Tlr4  NM_021297  0,82  0,0041  toll-like receptor 4  immune response; inflammatory response 
Fcgr2b  NM_010187  0,77  0,0000  Fc receptor  negative regulation of B-cell proliferation; negative 
regulation of immune response; positive regulation 
of phagocytosis; antigen presentation (exogenous 
peptide antigen via MHC class II) 
Ifi47  NM_008330  0,69  0,0044  interferon gamma inducible protein 47  defense response 
Ap3b1  NM_009680  0,67  0,0088  adaptor-related protein complex 3, beta 1 
subunit
antigen presentation & processing (exogenous lipid 
antigen); positive regulation of NK T-cell 
differentiation
Il18  NM_008360  0,66  0,0087  interleukin 18  immune response 
X97991  X97991  0,64  0,0010  calcitonin / calcitonin-related polypeptide  inflammatory response 
Ifi203  NM_008328  0,63  0,0049  interferon activated gene 203  immune response 
Bad  NM_007522  0,51  0,0090  Bcl-associated death promoter  positive regulation of B- & T-cell differentiation 
AB022307  AB022307  0,49  0,0055  interleukin 15  NK T-cell proliferation & differentiation; lymph 
gland development ; regulation of antiviral 
response
9230106L14Rik  NM_138685  0,48  0,0058  elafin-like protein I  defense response to bacteria 
Cxcl10  NM_021274  0,47  0,0009  chemokine ligand 10  chemotaxis; immune response; inflammatory 
response
Irf2  NM_008391  0,44  0,0083  interferon regulatory factor 2  immune response 
PROTEOLYSIS_________________________________________________________________________________________________________________
Gene name  Accession 
number 
Ratio t-test 
p-value 
Product Biological  process 
Mst1  NM_008243  2,08  0,0019  macrophage stimulating 1  proteolysis and peptidolysis 
Zfp61  NM_009561  2,03  0,0075  zinc finger protein 61  proteolysis and peptidolysis 
AK081629  AK081629  1,76  0,0089  dual specificity phosphatase 11  protein amino acid dephosphorylation 
F12  NM_021489  1,42  0,0038  coagulation factor XII  proteolysis and peptidolysis 
BC027403  BC027403  1,17  0,0014  bleomycin hydrolase  proteolysis and peptidolysis 
AK036071 AK036071  0,75  0,0050  membrane-bound  transcription  factor 
protease
proteolysis and peptidolysis 
Col6a1  NM_009933  0,72  0,0018  procollagen, type VI, alpha 1  proteolysis and peptidolysis 
Casp2  NM_007610  0,71  0,0037  caspase 2  proteolysis and peptidolysis 
Enpep  NM_007934  0,70  0,0021  glutamyl aminopeptidase  proteolysis and peptidolysis 
AK041155  AK041155  0,70  0,0015  CDC14 cell division cycle 14 homolog B  protein amino acid dephosphorylation 
BC050834  BC050834  0,70  0,0095  metalloprotease  proteolysis and peptidolysis 
Casp6  NM_009811  0,69  0,0038  caspase 6  proteolysis and peptidolysis 
Hspa14  NM_015765  0,68  0,0062  heat shock protein 14  proteolysis and peptidolysis 
Cflar  NM_009805  0,68  0,0089  CASP8 & FADD-like apoptosis regulator 
isoform 1 & 2 
proteolysis and peptidolysis 
Ndst1  NM_008306  0,67  0,0079  N-deacetylase / N-sulfotransferase 1  proteolysis and peptidolysis 
Ube3a  NM_011668  0,65  0,0043  ubiquitin protein ligase E3A isoform 1 & 2  protein modification; ubiquitin-dependent protein 
catabolism
Pep4  NM_008820  0,65  0,0101  peptidase 4  collagen catabolism; proteolysis and peptidolysis 
Spc18  NM_019951  0,63  0,0090  Sec11-like 1  proteolysis and peptidolysis 
Pten  NM_008960  0,61  0,0050  phosphatase and tensin homolog  protein amino acid dephosphorylation 
Ubl3 NM_011908  0,61  0,0081  ubiquitin-like  3  protein  modification 
AK083534  AK083534  0,57  0,0080  metalloprotease  proteolysis and peptidolysis 
Casp12  NM_009808  0,57  0,0055  caspase 12  proteolysis and peptidolysis 
Proz  NM_025834  0,56  0,0077  protein Z  proteolysis and peptidolysis 
Ptpn8  NM_008979  0,54  0,0024  protein tyrosine phosphatase  protein amino acid dephosphorylation 
Tpp2  NM_009418  0,54  0,0086  tripeptidyl peptidase II  proteolysis and peptidolysis 
BC057997  BC057997  0,53  0,0048  proteasome 26S ATPase subunit 6  protein catabolism 
AK082233 AK082233  0,51  0,0055  protein  modification 
Ube1c  NM_011666  0,50  0,0061  ubiquitin-activating enzyme E1C  protein modification 
Cpa3  NM_007753  0,44  0,0015  carboxypeptidase A3  proteolysis and peptidolysis 
AK078301  AK078301  0,44  0,0096  dipeptidylpeptidase 9  proteolysis and peptidolysis 
Yme1l1  NM_013771  0,43  0,0044  YME1-like 1  protein catabolism; proteolysis and peptidolysis 